GlobeNewswire

Ballast Point® Releases Aloha Sculpin® IPA Nationwide

Dela

Brewery uses 'Brux Trois' yeast; turns award-winning flagship beer into tropical oasis

SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- By using a newly developed Belgian yeast strain in an award-winning IPA, Ballast Point continues to showcase its innovative spirit with Aloha Sculpin, the latest addition to the Sculpin IPA family - now available nationwide.

Aloha Sculpin IPA features a distinct yeast strain known as Saccharomyces "Bruxellensis" Trois, or Brux Trois, turning the flagship IPA into a tropical oasis with aromas and flavors of guava, mango, and pineapple without any fruit additions. While Belgian yeast strains are known for their clove and banana-like aroma, this strain bears exotic fruit aromas. It also adds a slight haze to the beer, creating a smooth mouthfeel to round out its juicy character.

Not only does this yeast strain add a unique flavor profile to the brew, but its use in Aloha Sculpin marks the first time an IPA brewed with Saccharomyces brux Trois is being packaged and made available nationwide.

"We're always experimenting with new ingredients and methods," said James Murray, vice president of brewing at Ballast Point. "Most brewers tend to experiment with hops for flavor and aroma. But when we tasted the guava, mango and pineapple notes from this yeast in other R&D recipes we brewed, we knew it would really enhance the bright, tropical fruit characteristics already present in Sculpin IPA."

Innovation is a part of Ballast Point's DNA and has been a critical part of the brewery's success dating back to the days of Home Brew Mart. As a pioneer in the San Diego craft beer movement, the brewery currently makes over 50 styles of beer, each with innovation and quality in mind. Experimenting with Brux Trois yeast is a testament to this focus.

"This strain is a bit finicky," said Lauren Zeidler, director of quality at Ballast Point. "It's very particular about what it likes and doesn't, so we had to get to know its preferences and adjust accordingly. It was a unique challenge, but it made the brewing and batch scaling even more of a satisfying accomplishment."

The original Sculpin IPA launched in 2005 and has since become the hallmark of the west coast-style IPA, winning gold medals at the World Beer Cup (2010, 2014) and European Beer Star (2010, 2011). Years later, the Sculpin family has expanded to include Grapefruit, Pineapple, Habanero, Unfiltered - and now Aloha Sculpin.

Aloha Sculpin IPA is a spring/summer seasonal release under Ballast Point's flagship tier and is now rolling out nationwide in both draft and six-pack bottles.

For more information, visit www.BallastPoint.com.

About Ballast Point Brewing Company
Started in 1996 by a small group of home brewers in San Diego, Ballast Point has a 20-plus-year history of supporting the art of home brewing and developing high-quality, innovative and award-winning beer. Ballast Point has become one of the nation's leading craft breweries by exploring new tastes and techniques to create the perfect balance of taste and aroma. At Ballast Point, a culture of quality persists from selection of raw materials to the brewing process to the finished product and beyond. From developing a proprietary yeast for our amber ale to creating a breakthrough gold medal-winning IPA, Ballast Point is dedicated to the craft of brewing beers for all to enjoy.

Media Contact:
Jennifer Dohm
312-741-2089
Jennifer.dohm@cbrands.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/35145537-1f86-4c08-9b33-453b9a5a96f8




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ballast Point Brewing Company via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum